enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Dec 22, 2016 → Jul 31, 2029
NCT ID
NCT02960022About enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02960022. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02960022 | Phase 2 | Recruiting |
Competing Products
20 competing products in Prostate Cancer